Elicio Therapeutics (ELTX) Net Cash Flow (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Net Cash Flow data on file, last reported at -$3.6 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 1831.1% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$4.1 million (down 163.34% YoY), and the FY2025 full-year result was -$273000.0, down 105.28% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$3.6 million, down from -$2.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $23.5 million in Q3 2024 and bottomed at -$15.7 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$1.1 million (2024), against an average of $325529.4.
• The widest annual swing landed in 2024, when Net Cash Flow jumped 554.16%; it then sank 1831.1% in 2026.
• A 5-year view of Net Cash Flow shows it stood at $3.8 million in 2022, then slumped by 176.06% to -$2.9 million in 2023, then plunged by 195.85% to -$8.6 million in 2024, then soared by 77.22% to -$2.0 million in 2025, then tumbled by 85.54% to -$3.6 million in 2026.
• The last three Net Cash Flow figures came in at -$3.6 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.

Peer Comparison